The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
AHL 2011: A Lysa randomized phase III study of a treatment driven by early PET response compared to a standard treatment in patients with Ann Arbor stage III-IV or high-risk IIB Hodgkin lymphoma.
Rene-Olivier Casasnovas
No relevant relationships to disclose
Michel Meignan
No relevant relationships to disclose
Oumedaly Reman
No relevant relationships to disclose
Isabelle Gaillard
No relevant relationships to disclose
Aspasia Stamatoullas
No relevant relationships to disclose
Pauline Brice
No relevant relationships to disclose
Gilles A. Salles
No relevant relationships to disclose
Reda Bouabdallah
No relevant relationships to disclose
Serge Bologna
No relevant relationships to disclose
Emmanuelle Nicolas-Virelizier
No relevant relationships to disclose
Franck Morschhauser
No relevant relationships to disclose
Maud Janvier
No relevant relationships to disclose
Marc Andre
No relevant relationships to disclose
Alina Berriolo-Riedinger
No relevant relationships to disclose
Alexandra Traverse-Glehen
No relevant relationships to disclose
Veronique Edeline
No relevant relationships to disclose
Peggy Dartigues
No relevant relationships to disclose
Marie Parrens
No relevant relationships to disclose
Nicolas Mounier
No relevant relationships to disclose
Christophe Ferme
No relevant relationships to disclose